干旱区生态环境知识资源中心(Arid): Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients

Arid

DOI	10.1016/j.humimm.2020.04.002
	Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients
	Jalalonmuhali, M.; Carroll, R. P.; Tsiopelas, E.; Clayton, P.; Coates, P. T.
通讯作者	Jalalonmuhali, M
来源期刊	HUMAN IMMUNOLOGY
ISSN	0198-8859
EISSN	1879-1166
出版年	2020
卷号	81 期号:7 页码:323-329
英文摘要	Background: Blood transfusion during the post-operative period of kidney transplantation is common as part of a life-saving procedure, especially in the event of acute blood loss. However, there have been conflicting opinions since the pre-cyclosporine era. The risk of sensitization post-transfusion remains the main limiting factor following transfusion in kidney transplant recipients. Thus, the objective of this study is to assess the development of de novo HLA-DSA, HLA-Ab and allograft rejection post blood transfusion. Methodology: This is a retrospective cohort study recruiting all kidney transplant recipients in South Australia from January 2010 till December 2018. Following that, the incidence of blood transfusion within one week post-operatively were traced (transfusion group). The outcomes were compared with all other transplant recipients (non-transfusion group). Recipient's demographic, donor characteristics and immunological risk profiles were obtained from the transplant unit database, while the biopsy report, history of blood transfusion, latest serum creatinine and follow-up status was gathered from the electronic medical system (OASIS). The HLA-DSA and HLA-Ab results were collected from the NOMS database. Finally, the survival data were merged with the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry for South Australia recipients graft survival. Results: A total of 699 patients were eligible for analysis. The mean age was 50.64 +/- 13.23 years old. There were more elderly (> 65 years old) and females who needed transfusion. The majority had glomerulonephritis as the primary disease. There was no statistical difference in donor characteristics, cold ischemic time and immunological risk between the transfusion and non-transfusion group. There was no difference in the development of de novo HLA-DSA, HLA-Ab and rejection episodes between the group and the results were consistent in a model adjusted for all potential confounders. Median graft survival in days between the transfusion vs non-transfusion group was 1845 IQR (961,2430) and 1250 IQR (672,2013). Conclusion: Blood transfusion under strong immunosuppressive cover within a one-week post-operative period is safe with no significant association with the development of de novo HLA-DSA, HLA-Ab or clinical rejection.
英文关键词	HLA donor specific antibodies HLA-DSA HLA antibodies HLA-Ab Allograft rejection Blood transfusion Kidney transplant recipients
类型	Article
语种	英语
收录类别	SCI-E
WOS记录号	WOS:000542078500002
WOS关键词	GRAFT-SURVIVAL ; SENSITIZATION ; CYCLOSPORINE ; RISK
WOS类目	Immunology
WOS研究方向	Immunology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/324807
作者单位	[Jalalonmuhali, M.] Univ Malaya, Med Ctr, Div Nephrol, Dept Med, Kuala Lumpur 59100, Malaysia; [Jalalonmuhali, M.; Carroll, R. P.; Clayton, P.; Coates, P. T.] Royal Adelaide Hosp, Cent Northern Adelaide Renal & Transplant Serv CN, Adelaide, SA 5000, Australia; [Carroll, R. P.; Tsiopelas, E.; Coates, P. T.] Womens & Childrens Hosp, South Australian Transplantat & Immunogenet Lab, Adelaide, SA 5006, Australia
推荐引用方式 GB/T 7714	Jalalonmuhali, M.,Carroll, R. P.,Tsiopelas, E.,et al. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients[J],2020,81(7):323-329.
APA	Jalalonmuhali, M.,Carroll, R. P.,Tsiopelas, E.,Clayton, P.,&Coates, P. T..(2020).Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.HUMAN IMMUNOLOGY,81(7),323-329.
MLA	Jalalonmuhali, M.,et al."Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients".HUMAN IMMUNOLOGY 81.7(2020):323-329.